Your SlideShare is downloading. ×
PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

82

Published on

The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. …

The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
82
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs,and more branded products are expected to lose market exclusivity during the next few years. GlobalDatapredicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHFmarket over the forecast period include the sparsely populated CHF pipeline and an increasing number ofgeneric competitors in a market that is already heavily laden with generic drugs.However, the market entry of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enterthe market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF),but if clinical trial data continue to demonstrate the drug’s efficacy in patients with heart failure withpreserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drugto show efficacy in this largely underserved patient population. In addition, increased use of MRAs over theforecast period in all seven major markets (7MM) will contribute to the increase in the global CHF marketsize.ScopeOverview of CHF, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines. Annualized CHF therapeutics market revenue, annual cost of therapy and treatment usage patterndata from 2011-2012 and forecast for ten years to 2022. Key topics covered include strategic competitorassessment, market characterization, unmet needs, clinical trial mapping and implications for the CHFtherapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trendsunder development, including both pharmacological and non-pharmacological therapeutic approaches.Analysis of the current and future market competition in the global CHF therapeutics market. Insightfulreview of the key industry drivers, restraints and challenges. Each trend is independently researched to providequalitative analysis of its implications.Market Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsAn increasing number of generic competitors present a significant barrier to growth in a market alreadyheavily laden with generic drugs. The launch of Novartis’s LCZ-696, a new market entrant, will drivethe overall growth of the CHF market in the 7MM during 2012-2022. To date, no drug has demonstratedsufficient efficacy in the HF-PEF segment of the CHF population in large-scale clinical trials. This unmetneed presents a large opportunity for investment by drug developers.Key Questions Answered in this ReportPharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 2. Although the CHF market has numerous well-established therapies, it is marked by the presence of a numberof unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs underdevelopment fulfil the unmet needs of the CHF market? The late-stage CHF developmental pipeline issparsely populated, however, the early stage pipeline is more active and consists of novel pharmacological aswell as non-pharmacological therapeutic approaches. Will the late-stage drugs make a significant impact onthe CHF market? What are the earlier-stage novel, approaches that drug developers are pursuing? Althoughthe incidence of CHF in the US has been relatively constant during the last decade, its prevalence has beengradually increasing. How will epidemiological changes impact the growth of the future market?Key BenefitsDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisitiontargets included in the pipeline product company list. Develop business strategies by understanding the trendsshaping and driving the global CHF therapeutics market. Drive revenues by understanding the key trends,innovative products and technologies, market segments, and companies likely to impact the global CHFtherapeutics market in future. Formulate effective sales and marketing strategies by understanding thecompetitive landscape and by analyzing the performance of various competitors. Identify emerging playerswith potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage. Track drug sales in the global CHF therapeutics market from 2012-2022. Organize your sales andmarketing efforts by identifying the market categories and segments that present maximum opportunities forconsolidations, investments and strategic partnerships.table Of Contents1table Of Contents11.1list Of Tables51.2list Of Figures62executive Summary72.1sales For Chronic Heart Failure By Region 2012–202282.2drug Developers Frequently Pursue Approval In Hypertension Prior To Seeking A Label Expansion IntoChronic Heart Failure102.3the Chronic Heart Failure Market Has Considerable Unmet Needs, Despite The Availability OfWell-established Treatments102.4market Opportunities For New Entrants112.5novel Combination Drug Lcz-696 Will Be A Major Market Player By 2022112.6what Do The Physicians Think?123introduction143.1catalyst143.2related Reports14PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 3. 3.3upcoming Related Reports144disease Overview154.1etiology And Pathophysiology154.1.1etiology154.1.2pathophysiology174.2prognosis194.3quality Of Life204.4symptoms215epidemiology215.1risk Factors And Comorbidities225.1.1age And Sex Are Highly Associated With The Risk Of Chronic Heart Failure225.1.2history Of Cardiovascular Disease Increases The Risk Of Developing Chronic Heart Failure235.1.3unhealthy Lifestyles Increase The Risk Of Chronic Heart Failure235.1.4people With Diabetes Mellitus Are Twice As Likely To Develop Chronic Heart Failure235.1.5nearly 20% Of Patients With Chronic Kidney Disease Develop Chronic Heart Failure235.1.6comorbidities245.1.7prognosis For Chronic Heart Failure Remains Poor255.2global Trends255.2.1united States255.2.2france265.2.3germany275.2.4italy275.2.5spain275.2.6united Kingdom285.2.7japan285.2.8china285.3forecast Methodology285.3.1sources Used285.3.2forecast Assumptions And Methods335.3.3forecast Assumptions And Methods For New York Heart Association Class Distributions355.3.4sources Not Used355.4epidemiology Forecast (2012–2022)365.4.1prevalent Cases Of Chronic Heart Failure365.4.2age-specific Prevalent Cases375.4.3sex-specific Prevalent Cases395.4.4age-standardized Prevalence425.4.5new York Heart Association Class Distributions445.5discussion445.5.1limitations Of Analysis45PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 4. 5.5.2strengths Of Analysis466disease Management466.1treatment Overview476.1.1pharmacological Treatments496.1.2mechanical Devices546.2us556.2.1diagnosis And Referral Patterns556.2.2clinical Practice566.3france576.3.1diagnosis And Referral Patterns576.3.2clinical Practice586.4germany586.4.1diagnosis And Referral Patterns586.4.2clinical Practice596.5italy606.5.1diagnosis And Referral Patterns606.5.2clinical Practice606.6spain616.6.1diagnosis And Referral Patterns616.6.2clinical Practice616.7uk626.7.1diagnosis And Referral Patterns626.7.2clinical Practice636.8japan646.8.1diagnosis And Referral Patterns646.8.2clinical Practice647competitive Assessment657.1overview657.2strategic Competitor Assessment657.3drug Profiles697.3.1angiotensin-converting Enzyme (ace) Inhibitors697.3.2diuretics717.3.3angiotensin Receptor Blockers747.3.4beta Blockers847.3.5procoralan (ivabradine)937.3.6mineralocorticoid Receptor Antagonists967.3.7digoxin99PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 5. 8opportunity And Unmet Need1018.1overview1018.2lack Of Therapies For Hf-pef Patients1028.3lack Of Therapies For Patients With Renal Impairment1038.4diagnosis Of Asymptomatic Left Ventricular Dysfunction1038.5treatment Of Patients With Multiple Comorbidities1048.6increase In Survival Of Chf Patients1048.7unmet Needs Gap Analysis1058.8opportunity: Treatment Of Patients With Hf-pef1068.9opportunity: Therapies For Patients With Renal Impairment And Multiple Comorbidities1068.10opportunity: New Drugs That Show Increase In Survival Of Chf Patients1069pipeline Assessment1069.1overview1069.1.1clinical Trials By Country1089.2clinical Trials By Phase And Trial Status1099.3promising Drugs In Clinical Development1099.3.1lcz-6961119.3.2tekturna (aliskiren)1149.3.3neucardin (rhnrg-1)1179.4innovative Early-stage Approaches1219.4.1bay 94-88621219.4.2omecamtiv Mecarbil1239.5promising Non-pharmacological Approaches1259.5.1myocell1269.5.2c-cure (c3bs-cqr-1)1309.5.3mydicar (raav1-serca2a)13310current And Future Players13610.1overview13610.2trends In Corporate Strategy13710.3company Profiles13710.3.1novartis13711market Outlook14011.1global Markets14011.1.1forecast14011.1.2drivers And Barriers – Global Issues14211.2united States14411.2.1forecast144PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 6. 11.2.2key Events14611.2.3drivers And Barriers14711.3france14811.3.1forecast14811.3.2key Events15011.3.3drivers And Barriers15111.4germany15211.4.1forecast15211.4.2key Events15511.4.3drivers And Barriers15511.5italy15611.5.1forecast15611.5.2key Events15811.5.3drivers And Barriers15911.6spain16011.6.1forecast16011.6.2key Events16211.6.3drivers And Barriers16311.7united Kingdom16411.7.1forecast16411.7.2key Events16611.7.3drivers And Barriers16611.8japan16811.8.1forecast16811.8.2key Events17111.8.3drivers And Barriers17112appendix17212.1bibliography17212.2abbreviations18812.3methodology19112.4forecasting Methodology19112.4.1nyha Class Segmentation Of Total Prevalent Chf Population19112.4.2diagnosed Chf Population19212.4.3drug-treated Chf Population19212.4.4patient Population Breakdown: Hf-ref Versus Hf-pef19312.4.5treatment Of Hf-ref Versus Hf-pef19312.4.6drugs Included In Each Therapeutic Class19312.4.7launch And Patent Expiry Dates19412.4.8general Pricing Assumptions19412.4.9drugs Assumptions19512.4.10generic Erosion200PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022
  • 7. 12.4.11pricing Of Pipeline Agents20012.5physicians And Specialists Included In This Study20112.6survey Of Prescribing Physicians20212.7about The Authors20312.7.1author20312.7.2epidemiologist20312.7.3global Head Of Healthcare20412.8about Globaldata20512.9contact Us20512.10disclaimer205ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

×